CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Editorial Board

Arthur J. Atkinson, Jr., M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Edward A. Carr, Jr., M.D.
Leighton E. Cluff, M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Henry W. Elliott, M.D., Ph.D.
Karl Engelman, M.D.
Alvan R. Feinstein, M.D.
Max Fink, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Franz Gross, M.D.
Arthur Hull Hayes, Jr., M.D.
Leo E. Hollister, M.D.
Bartholomew P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Ernest Jawetz, M.D., Ph.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Joseph B. Kirsner, M.D., Ph.D.
Kenneth G. Kohlstaedt, M.D.
Louis Lasagna, M.D.
D. R. Laurence, M.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
Daniel S. Lukas, M.D.
Fletcher H. McDowell, M.D.
Dean T. Mason, M.D.
R. K. Richards, M.D.
Jay Tepperman, M.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.
Graham M. Wilson, M.D., F.R.C.P., F.R.C.P.E.

Volume 19, January-June, 1976
The C. V. Mosby Company, St. Louis

Volume 19
Copyright © 1976 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 19

Author index

A

ABRAMS, W. B. A message from the President, American Society for Clinical Pharmacology and Therapeutics, 249

ACHONG, M. R., PIAFSKY, K. M., AND OGILVIE, R. I. Duration of cardiac effects of timolol and propranolol, 148

AHMAD, U. (*See* Danowski et al.), 196

AHMANN, D. L., BISEL, H. F., EDMONSON, J. H., HAHN, R. G., EAGAN, R. T., O'CONNELL, M. J., AND FRYTAK, S. Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma, 821

ALLEN, L. M. (*See* Nelson et al.), 365

ALTSCHULE, M. D., AND HEGEDUS, Z. L. The importance of studying visceral melanins, 124 (Commentary)

ALVARES, A. P., FISCHBEIN, A., SASSA, S., ANDERSON, K. E., AND KAPPAS, A. Lead intoxication: Effects of cytochrome P-450–mediated hepatic oxidations, 183

—. (*See* Anderson et al.), 47

ANDERSON, K. E., ALVARES, A. P., SASSA, S., AND KAPPAS, A. Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria, 47

—. (*See* Alvares et al.), 183

ANG, M. (*See* Nagashima et al.), 738

ARONOW, W. S. (*See* Prakash and Aronow), 94 (Correspondence)

ATKINSON, A. J., JR. (*See* Lee et al.), 508

ATWOOD, G. F. (*See* Wilson et al.), 264

AZARNOFF, D. L. (*See* Dujovne et al.), 352

—. (*See* Gugler et al.), 135

—. (*See* Huffman et al.), 807

B

BAETHKE, R. (*See* Vöhringer et al.), 387

BALTES, B. J. (*See* Karim et al.), 170

BARBER, H. E. (*See* Calvey et al.), 813

BECH, P. (*See* Gram et al.), 318

BEERMANN, B., GROSCHINSKY-GRIND, M., AND ROSÉN, A. Absorption, metabolism, and excretion of hydrochlorothiazide, 531

BELLVILLE, J. W. (*See* Conner et al.), 24

BENET, L. Z. (*See* Galeazzi et al.), 55; 830 (Correspondence)

BERGER, F. M. Present status of clinical psychopharmacology, 725 (Commentary)

BIGGER, J. T., JR. (*See* Giardina et al.), 339

BIGGS, J. T. (*See* Ziegler et al.), 795

BINNS, T. B., GROSS, F., LASAGNA, L., AND NICOLIS, F. B., 247 (Correspondence)

BIRON, P., AND TREMBLAY, G. Acebutolol: Basis for the prediction of effect on exercise tolerance, 333

BISEL, H. F. (*See* Ahmann et al.), 821

BIXLER, E. O. (*See* Kales et al.), 576

BLACKWELL, B. Culture, morbidity, and the effects of drugs, 668

BOTERO, D. Clinical trial methodology in intestinal parasitic diseases, 630

BOWMAN, D. H. (*See* Danowski et al.), 196

BRANCH, R. A., READ, P. R., LEVINE, D., VANDER ELST, E., SHELTON, J., RUPP, W., AND RAMSAY, L. E. Furosemide and bumetanide: A study of responses in normal English and German subjects, 538

BRIGGS, W. A. (*See* Gibson et al.), 206

BROWN, B. W., JR. (*See* Mahler et al.), 18

BROWN, C. R. (*See* Mahler et al.), 18

BUCHANAN, R. A., KINKEL, A. W., TURNER, J. L., AND HEFFELFINGER, J. C. Ethosuximide dosage regimens, 143

BYE, C. (*See* Johnson et al.), 746

C

CALDWELL, J. H., AND CLINE, C. T. Biliary excretion of digoxin in man, 410

CALVEY, T. N., WILLIAMS, N. E., MUIR, K. T., AND BARBER, H. E. Plasma concentration of edrophonium in man, 813

CARSON, P. E. (*See* Trenholme et al.), 459

CAVNESS, C. (*See* Feinberg et al.), 782

CEDILLOS, R. A. Variations in disease prevalence in the Americas, 675

CHAO, A. (*See* Karim et al.), 170

CHARLES, D. (*See* Philipson et al.), 68

CHARUVASTRA, V. C. (*See* Gritz et al.), 773

CHRISTIANSEN, J. (*See* Gram et al.), 318

CLARE, R. A. (*See* Dollery et al.), 11

—. (*See* Draffan et al.), 271

CLARK, S. C., JASINSKI, D. R., PEVNICK, J. S., AND GRIFFITH, J. D. Azidomorphine: Subjective effects and suppression of morphine abstinence, 295

CLAYTON, P. J. (*See* Ziegler et al.), 795

CLINE, C. T. (*See* Caldwell and Cline), 410

January, pp. 1-120; February, pp. 121-250; March, pp. 251-382; April, pp. 383-488; May, part 1, pp. 489-604; May, part 2, pp. 605-724; June, pp. 725-848.

Co, B. T. (*See* Ziegler et al.), 795
Comber, R. H. (*See* Singh et al.), 493
Conner, J. T., Parson, N., Katz, R. L., Wapner, S., and Bellville, J. W. Evaluation of lorazepam and pentobarbital as surgical premedicants, 24
Craig, C. P., and Rifkin, S. I. Pharmacokinetics and hemodialyzability of cefazolin in uremic patients, 825
Craig, W. A. (*See* Welling et al.), 559
Creaven, P. J. (*See* Nelson et al.), 365
Cressman, W. A., Wortham, G. F., and Plostnieks, J. Absorption and excretion of tolmetin in man, 224
Cumming, J. F. The effect of arterial oxygen tension on antipyrine half-time in plasma, 468
Cushman, P., and Khurana, R. Marijuana and T lymphocyte rosettes, 310

D

Dahl, S. G. Pharmacokinetics of methotrimeprazine after single and multiple doses, 435
Dalton, W. S., Martz, R., Lemberger, L., Rodda, B. E., and Forney, R. B. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects, 300
Danowski, T. S., Stephan, T., Nolan, S., Ahmad, U., Wingert, J. P., Jr., Bowman, D. H., Sunder, J. H., and Fisher, E. R. Thyroid hormone–like effects without thyrotoxicosis during one year's therapy with NA-DT_3, for hypercholesterolemia, 196
Dargie, H. J. (*See* Dollery et al.), 11
Darling, M. (*See* Draffan et al.), 271
Davies, D. S. (*See* Dollery et al.), 11
—. (*See* Draffan et al.), 271
Dean, C. R. (*See* Dollery et al.), 11
Dencker, H., Dencker, S. J., Green, A., and Nagy, A. Intestinal absorption, demethylation, and enterohepatic circulation of imipramine, 584
Dencker, S. J. (*See* Dencker et al.), 584
—. (*See* Gram et al.), 318
Dollery, C. T. Drug regulation in the United Kingdom, 689
—. Welcome, 605
—, Davies, D. S., Draffan, G. H., Dargie, H. J., Dean, C. R., Reid, J. L., Clare, R. A., and Murray, S. Clinical pharmacology and pharmacokinetics of clonidine, 11
—. (*See* Draffan et al.), 271
—. (*See* Myers et al.), 502
Dooley, M. (*See* Karim et al.), 158, 177
Draffan, G. H., Dollery, C. T., Davies, D. S., Krauer, B., Williams, F. M., Clare, R. A., Trudinger, B. J., Darling, M., Sertel, H., and Hawkins, D. F. Maternal and neonatal elimination of amobarbital after treatment of the mother with barbiturates during late pregnancy, 271
—. (*See* Dollery et al.), 11
Dreyfuss, J. (*See* Giardina et al.), 339
Duce, B. R. (*See* Lalka et al.), 757
Dujovne, C. A., Azarnoff, D. L., Huffman, D. H., Pentikäinen, P., Hurwitz, A., and Shoeman, D. W. One-year trials with halofenate, clofibrate, and placebo, 352
—. (*See* Huffman et al.), 807
Dutcher, J. S. (*See* Lee et al.), 508
Dzindzio, B. S. (*See* Ueda et al.), 30

E

Eagan, R. T. (*See* Ahmann et al.), 821
Earhart, R. H. (*See* Wilkinson et al.), 213
Edmonson, J. H. (*See* Ahmann et al.), 821
Ellard, G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis, 610
Elvin, A. T. (*See* Lalka et al.), 757
Engel, T. R., Soly, K. L., Meister, S. G., and Frankl, W. S. Effect of lidocaine on right ventricular muscle refractoriness, 515
Evans, M. A., Martz, R., Lemberger, L., Rodda, B. E., and Forney, R. B. Effects of dextroamphetamine on psychomotor skills, 777

F

Feinberg, I., Jones, R., Walker, J., Cavness, C., and Floyd, T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns, 782
Feinstein, A. R. Clinical biostatistics
XXXV. The persistent clinical failures and fallacies of the UGDP study, 78
XXXVI. The persistent biometric problems of the UGDP study, 472
Fischbein, A. (*See* Alvares et al.), 183
Fischer, L. J. (*See* Miller et al.), 284
Fisher, E. R. (*See* Danowski et al.), 196
Fleckenstein, L., Mundy, G. R., Horovitz, R. A., and Mazzullo, J. M. Sodium salicylamide: Relative bioavailability and subjective effects, 451
Floyd, T. (*See* Feinberg et al.), 782
Foldes, F. F. (*See* Nagashima et al.), 738
Forney, R. B. (*See* Dalton et al.), 300
—. (*See* Evans et al.), 777
Forrest, W. H., Jr. (*See* Mahler et al.), 18
Franke, K. (*See* Greenblatt et al.), 234
Frankl, W. S. (*See* Engel et al.), 515
Frischer, H. (*See* Trenholme et al.), 459
Frytak, S. (*See* Ahmann et al.), 821

G

Galeazzi, R. L., Sheiner, L. B., Lockwood, T., and Benet, L. Z. The renal elimination of procainamide, 55
—, —, —, and —, 830 (Correspondence)

GIARDINA, E-G. V., DREYFUSS, J., BIGGER, J. T., JR., SHAW, J. M., AND SCHREIBER, E. C. Metabolism of procainamide in normal and cardiac subjects, 339
GIBSON, T. P., MATUSIK, E. J., AND BRIGGS, W. A. N-acetylprocainamide levels in patients with end-stage renal failure, 206
GOLDFARB, T., GRITZ, E. R., JARVIK, M. E., AND STOLERMAN, I. P. Reactions to cigarettes as a function of nicotine and "tar," 767
GORDON, H. E. (*See* Mahler et al.), 18
GORODISCHER, R., JUSKO, W. J., AND YAFFE, S. J. Tissue and erythrocyte distribution of digoxin in infants, 256
GOULET, J. R. (*See* Smith et al.), 802
GRAM, L. F., REISBY, N., IBSEN, I., NAGY, A., DENCKER, S. J., BECH, P., PETERSEN, G. O., AND CHRISTIANSEN, J. Plasma levels and antidepressive effect of imipramine, 318
GRAY, P. (*See* Peterson et al.), 63
GREEN, A. (*See* Dencker et al.), 584
GREENBLATT, D. J., SHADER, R. I., HARMATZ, J. S., FRANKE, K., AND KOCH-WESER, J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption, 234
—. (*See* Stanski et al.), 752
GRIFFITH, J. D. (*See* Clark et al.), 295
GRITZ, E. R., SHIFFMAN, S. M., JARVIK, M. E., SCHLESINGER, J., AND CHARUVASTRA, V. C. Naltrexone: Physiological and psychological effects of single doses, 773
—. (*See* Goldfarb et al.), 767
GROSCHINSKY-GRIND, M. (*See* Beermann et al.), 531
GROSS, F. The present dilemma of drug research, 1 (Commentary)
—. (*See* Binns et al.), 247 (Correspondence)
GRYCZKO, C. M. (*See* Smith et al.), 802
GUGLER, R., MANION, C. V., AND AZARNOFF, D. L. Phenytoin: Pharmacokinetics and bioavailability, 135
GÜLLNER, H.-G., 599 (Correspondence)

H

HAHN, R. G. (*See* Ahmann et al.), 821
HAMER, J. (*See* Kaye et al.), 416
HAMPL, H. (*See* Vöhringer et al.), 387
HANSEN, J. M. (*See* Lund et al.), 587
HANSSON, L. (*See* Zweifler and Hansson), 403
HARMATZ, J. S. (*See* Greenblatt et al.), 234
HARRIS, E. A. (*See* Singh et al.), 493
HÄRTEL, G., KYLLÖNEN, K., MERIKALLIO, E., OJALA, K., MANNINEN, V., AND REISSELL, P. Human serum and myocardium digoxin, 153
HAWKINS, D. F. (*See* Draffan et al.), 271
HEFFELFINGER, J. C. (*See* Buchanan et al.), 143
HEGEDUS, Z. L. (*See* Altschule and Hegedus), 124 (Commentary)
HELFANT, R. H. (*See* Shah et al.), 732
HIEB, E. (*See* Wang et al.), 191
HIRSCHFELD, D. S. (*See* Ueda et al.), 30
HÖJER, B. (*See* Rane et al.), 276
HOROVITZ, R. A. (*See* Fleckenstein et al.), 451
HRIBAR, J. (*See* Karim et al.), 158
HUFFMAN, D. H., AZARNOFF, D. L., SHOEMAN, D. W., AND DUJOVNE, C. A. The interaction between halofenate and propranolol, 807
—. (*See* Dujovne et al.), 352
HUNT, S. N., JUSKO, W. J., AND YURCHAK, A. M. Effect of smoking on theophylline disposition, 546
HURWITZ, A. (*See* Dujovne et al.), 352
HUTSELL, T. C. (*See* Karim et al.), 170, 177
HVIDBERG, E. F. Drug evaluation, educational system, and clinical pharmacologic training in a small country, 718

I

IBSEN, I. (*See* Gram et al.), 318
INABA, T. (*See* Mahon et al.), 443, 566
INTURRISI, C. E. (*See* Mendelson et al.), 371

J

JAMES, K. E. (*See* Mahler et al.), 18
JARVIK, M. E. (*See* Goldfarb et al.), 767
—. (*See* Gritz et al.), 773
JASINSKI, D. R. (*See* Clark et al.), 295
JEFFERY, G. Introduction, 607
JENNE, J. W., NAGASAWA, H. T., AND THOMPSON, R. D. Relationship of urinary metabolites of theophylline to serum theophylline levels, 375
JOHNSON, B. F., BYE, C., JONES, G., AND SABEY, G. A. A completely absorbed oral preparation of digoxin, 746
JONES, G. (*See* Johnson et al.), 746
JONES, R. (*See* Feinberg et al.), 782
JUSKO, W. J. (*See* Gorodischer et al.), 256
—. (*See* Hunt et al.), 546

K

KAHN, A. Serum triiodothyronine levels in patients receiving L-thyroxine, 523
KÁLDOR, A. Patterns and problems of drug consumption in a developing country, 657
KALES, A., BIXLER, E. O., SCHARF, M., AND KALES, J. D. Sleep laboratory studies of flurazepam: A model for evaluating hypnotic drugs, 576
KALES, J. D. (*See* Kales et al.), 576
KAMPMANN, J. P. (*See* Lund et al.), 587
KANAKIS, C., 94 (Correspondence)
KAPPAS, A. (*See* Alvares et al.), 183
—. (*See* Anderson et al.), 47
KARAMANIAN, A. (*See* Nagashima et al.), 738
KARCH, F. E., SMITH, C. L., KERZNER, B., MAZZULLO, J. M., WEINTRAUB, M., AND LASAGNA, L. Adverse drug reactions—a matter of opinion, 489 (Commentary)

KARIM, A., ZAGARELLA, J., HRIBAR, J., AND DOOLEY, M. Spironolactone. I. Disposition and metabolism, 158
—, —, HUTSELL, T. C., CHAO, A., AND BALTES, B. J. Spironolactone. II. Bioavailability, 170
—, —, —, AND DOOLEY, M. Spironolactone. III. Canrenone—maximum and minimum steady-state plasma levels, 177
KATZ, R. L. (*See* Conner et al.), 24
KAYE, C. M., KUMANA, C. R., LEIGHTON, M., HAMER, J., AND TURNER, P. Observations on the pharmacokinetics of acebutolol, 416
KEHOE, R. F. (*See* Lee et al.), 508
KERZNER, B. (*See* Karch et al.), 489 (Commentary)
KHURANA, R. (*See* Cushman and Khurana), 310
KINKEL, A. W. (*See* Buchanan et al.), 143
—. (*See* Smith et al.), 802
KISSNER, P. Z. (*See* Lazar and Kissner), 598 (Correspondence)
KLASTERSKY, J. (*See* Rozencweig et al.), 592
KOCH-WESER, J., 830 (Correspondence)
—. (*See* Greenblatt et al.), 234
—. (*See* Stanski et al.), 752
KOERNER, S. (*See* Nagashima et al.), 738
KRAUER, B. (*See* Draffan et al.), 271
KUHLMANN, J. (*See* Vöhringer et al.), 387
KUMANA, C. R. (*See* Kaye et al.), 416
KYLLÖNEN, K. (*See* Härtel et al.), 153

L

LALKA, D., MEYER, M. B., DUCE, B. R., AND ELVIN, A. T. Kinetics of the oral antiarrhythmic lidocaine congener, tocainide, 757
LAPPAS, D. G. (*See* Stanski et al.), 752
LASAGNA, L. (*See* Binns et al.), 247 (Correspondence)
—. (*See* Karch et al.), 489 (Commentary)
LAZAR, J. D., AND KISSNER, P. Z., 598 (Correspondence)
LEE, W.-K., STRONG, J. M., KEHOE, R. F., DUTCHER, J. S., AND ATKINSON, A. J., JR. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions, 508
LEIGHTON, M. (*See* Kaye et al.), 416
LEMBERGER, L. (*See* Dalton et al.), 300
—. (*See* Evans et al.), 777
LEVINE, D. (*See* Branch et al.), 538
LEVY, G. (*See* Yacobi et al.), 552
LEWIS, G. R. J. (*See* Myers et al.), 502
LILIENFIELD, L. S., ROSE, J. C., AND PRINCIOTTO, J. V. Antitussive activity of diphenhydramine in chronic cough, 421
LINDAHL, F. (*See* Lund et al.), 587
LOCKWOOD, T. (*See* Galeazzi et al.), 55; 830 (Correspondence)
LONG, G. (*See* Thomas et al.), 426
LOWENSTEIN, E. (*See* Stanski et al.), 752
LUND, B., KAMPMANN, J. P., LINDAHL, F., AND HANSEN, J. M. Pivampicillin and ampicillin in bile, portal and peripheral blood, 587
LYONS, L. L. (*See* Welling et al.), 559

M

MCDEVITT, D. G., NIES, A. S., WILKINSON, G. R., SMITH, R. F., WOOSLEY, R. L., AND OATES, J. A. Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2′,6′-propionoxylidide, in man, 396
MAHLER, D. L., FORREST, W. H., JR., BROWN, C. R., SHROFF, P. F., GORDON, H. E., BROWN, B. W., JR., AND JAMES, K. E. Assay of aspirin and naproxen analgesia, 18
MAHON, W. A., INABA, T., UMEDA, T., TSUTSUMI, E., AND STONE, R. Biliary elimination of diazepam in man, 443
—, MAYERSOHN, M., AND INABA, T. Disposition kinetics of two oral forms of quinidine, 566
MALOVANY, R. (*See* Nagashima et al.), 738
MANION, C. V. (*See* Gugler et al.), 135
MANNINEN, V. (*See* Härtel et al.), 153
MÄNNISTÖ, P. T. Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women, 37
MARTZ, R. (*See* Dalton et al.), 300
—. (*See* Evans et al.), 777
MATERSON, B. J., OSTER, J. R., MICHAEL, U. F., AND PEREZ-STABLE, E. C. Antihypertensive effectiveness of oxprenolol administered twice daily, 325
MATHER, L. E., 246 (Correspondence)
MATUSIK, E. J. (*See* Gibson et al.), 206
MAYERSOHN, M. (*See* Mahon et al.), 566
MAZZULLO, J. M. (*See* Fleckenstein et al.), 451
—. (*See* Karch et al.), 489 (Commentary)
MEISTER, S. G. (*See* Engel et al.), 515
MENDELSON, J. H., INTURRISI, C. E., RENAULT, P., AND SENAY, E. C. Effects of acetylmethadol on plasma testosterone, 371
MERIKALLIO, E. (*See* Härtel et al.), 153
MEYER, M. B. (*See* Lalka et al.), 757
MICHAEL, U. F. (*See* Materson et al.), 325
MILLER, R. P., ROBERTS, R. J., AND FISCHER, L. J. Acetaminophen elimination kinetics in neonates, children, and adults, 284
MODELL, W. Progress with protection, 121 (Editorial)
MOORE, G., AND NATION, R., 246, 486 (Correspondence)
—. (*See* Thomas et al.), 426
MORGAN, D. (*See* Thomas et al.), 426
MORGAN, J. P. A bureaucratic determinant of scientific precedence or: "Scooped by the drug lag," 383 (Commentary)
MUIR, K. T. (*See* Calvey et al.), 813
MUNDY, G. R. (*See* Fleckenstein et al.), 451

MURRAY, S. (*See* Dollery et al.), 11
MYERS, M. G., LEWIS, G. R. J., STEINER, J., AND DOLLERY, C. T. Atenolol in essential hypertension, 502

N

NAGASAWA, H. T. (*See* Jenne et al.), 375
NAGASHIMA, H., KARAMANIAN, A., MALOVANY, R., RADNAY, P., ANG, M., KOERNER, S., AND FOLDES, F. F. Respiratory and circulatory effects of intravenous butorphanol and morphine, 738
NAGY, A. (*See* Dencker et al.), 584
—. (*See* Gram et al.), 318
NATION, R. (*See* Moore and Nation), 246, 486 (Correspondence)
NELSON, R. L., ALLEN, L. M., AND CREAVEN, P. J. Pharmacokinetics of divided-dose ifosfamide, 365
NICOLIS, F. B. (*See* Binns et al.), 247 (Correspondence)
NIES, A. S. (*See* McDevitt et al.), 396
NOLAN, S. (*See* Danowski et al.), 196

O

OATES, J. A. (*See* McDevitt et al.), 396
O'CONNELL, M. J. (*See* Ahmann et al.), 821
OGILVIE, R. I. (*See* Achong et al.), 148
OJALA, K. (*See* Härtel et al.), 153
OSTER, J. R. (*See* Materson et al.), 325

P

PARSON, N. (*See* Conner et al.), 24
PELTIER, H. C. Introduction, 628
PENTIKÄINEN, P. (*See* Dujovne et al.), 352
PEREZ-STABLE, E. C. (*See* Materson et al.), 325
PETERSEN, G. O. (*See* Gram et al.), 318
PETERSON, P., GRAY, P., AND TOLMAN, K. G. Calcium balance in drug-induced osteomalacia: Response to vitamin D, 63
PEVNICK, J. S. (*See* Clark et al.), 295
PHILIPSON, A., SABATH, L. D., AND CHARLES, D. Erythromycin and clindamycin absorption and elimination in pregnant women, 68
PIAFSKY, K. M. (*See* Achong et al.), 148
PLOSTNIEKS, J. (*See* Cressman et al.), 224
PRAKASH, R., AND ARONOW, W. S., 94 (Correspondence)
PRINCIOTTO, J. V. (*See* Lilienfield et al.), 421

R

RADNAY, P. (*See* Nagashima et al.), 738
RAMSAY, L. E. (*See* Branch et al.), 538
RAMSAY, R. E. (*See* Wilder and Ramsay), 360
RANE, A., HÖJER, B., AND WILSON, J. T. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children, 276
READ, P. R. (*See* Branch et al.), 538
REID, J. L. (*See* Dollery et al.), 11
REISBY, N. (*See* Gram et al.), 318
REISSELL, P. (*See* Härtel et al.), 153
RENAULT, P. (*See* Mendelson et al.), 371
RIECKMANN, K. H. (*See* Trenholme et al.), 459
RIETBROCK, N. (*See* Vöhringer et al.), 387
RIFKIN, S. I. (*See* Craig and Rifkin), 825
ROBERTS, R. J. (*See* Miller et al.), 284
RODDA, B. E. (*See* Dalton et al.), 300
—. (*See* Evans et al.), 777
ROSE, J. C. (*See* Lilienfield et al.), 421
ROSÉN, A. (*See* Beermann et al.), 531
ROWLAND, M. (*See* Ueda et al.), 30
ROZENCWEIG, M., STAQUET, M., AND KLASTERSKY, J. Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin, 592
RUPP, W. (*See* Branch et al.), 538

S

SABATH, L. D. (*See* Philipson et al.), 68
SABEY, G. A. (*See* Johnson et al.), 746
SAKMAR, E. (*See* Wilkinson et al.), 213
SAKUMA, A. Regulatory differences and similarities: Systems in Japan, 694
SASSA, S. (*See* Alvares et al.), 183
—. (*See* Anderson et al.), 47
SCHARF, M. (*See* Kales et al.), 576
SCHEINMAN, M. M. (*See* Ueda et al.), 30
SCHENKER, S. (*See* Wilkinson and Schenker), 486 (Correspondence)
SCHLESINGER, J. (*See* Gritz et al.), 773
SCHREIBER, E. C. (*See* Giardina et al.), 339
SEDMAN, A. J. (*See* Wilkinson et al.), 213
SENAY, E. C. (*See* Mendelson et al.), 371
SERTEL, H. (*See* Draffan et al.), 271
SHADER, R. I. (*See* Greenblatt et al.), 234
SHAH, R. S., WALKER, B. R., VANOV, S. K., AND HELFANT, R. H. Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension, 732
SHAND, D. G. (*See* Wilson et al.), 264
SHAW, J. M. (*See* Giardina et al.), 339
SHEINER, L. B. (*See* Galeazzi et al.), 55; 830 (Correspondence)
SHELTON, J. (*See* Branch et al.), 538
SHETH, U. K. Regulatory milieu in India, 704
SHIFFMAN, S. M. (*See* Gritz et al.), 773
SHOEMAN, D. W. (*See* Dujovne et al.), 352
—. (*See* Huffman et al.), 807
SHROFF, P. F. (*See* Mahler et al.), 18
SICÉ, J. Of sponsored tasks and public service, 251 (Editorial)
SINGH, B. N., WHITLOCK, R. M. L., COMBER, R. H., WILLIAMS, F. H., AND HARRIS, E. A. Effects of cardioselective beta blockade on specific airways resistance in normal subjects and in patients with bronchial asthma, 493
SMITH, C. L. (*See* Karch et al.), 489 (Commentary)
SMITH, R. F. (*See* McDevitt et al.), 396
SMITH, T. C., KINKEL, A. W., GRYCZKO, C. M., AND GOULET, J. R. Absorption of pyrvinium pamoate, 802

SMYTH, A. C., AND WIERNIK, P. H. Combination chemotherapy of adult acute lymphocytic leukemia, 240
SOLY, K. L. (*See* Engel et al.), 515
SPURNY, P. (*See* Vöhringer et al.), 387
STANSKI, D. R., GREENBLATT, D. J., LAPPAS, D. G., KOCH-WESER, J., AND LOWENSTEIN, E. Kinetics of high-dose intravenous morphine in cardiac surgery patients, 752
STAQUET, M. (*See* Rozencweig et al.), 592
STEINER, J. (*See* Myers et al.), 502
STEPHAN, T. (*See* Danowski et al.), 196
STOCKDALE, S. L. (*See* Wang et al.), 191
STOLERMAN, I. P. (*See* Goldfarb et al.), 767
STOLLEY, P. D. How study of geographic epidemiology of disease can help in detection of adverse drug reactions, 679
STONE, R. (*See* Mahon et al.), 443
STRONG, J. M. (*See* Lee et al.), 508
SUNDER, J. H. (*See* Danowski et al.), 196

T

TAYLOR, J. R. (*See* Ziegler et al.), 795
THOMAS, J., LONG, G., MOORE, G., AND MORGAN, D. Plasma protein binding and placental transfer of bupivacaine, 426
THOMPSON, R. D. (*See* Jenne et al.), 375
TOLMAN, K. G. (*See* Peterson et al.), 63
TREMBLAY, G. (*See* Biron and Tremblay), 333
TRENHOLME, G. M., WILLIAMS, R. L., RIECKMANN, K. H., FRISCHER, H., AND CARSON, P. E. Quinine disposition during malaria and during induced fever, 459
TRUDINGER, B. J. (*See* Draffan et al.), 271
TSE, F. L. S. (*See* Welling et al.), 559
TSUTSUMI, E. (*See* Mahon et al.), 443
TURNER, J. L. (*See* Buchanan et al.), 143
TURNER, P. (*See* Kaye et al.), 416

U

UDALL, J. A. (*See* Yacobi et al.), 552
UEDA, C. T., HIRSCHFELD, D. S., SCHEINMAN, M. M., ROWLAND, M., WILLIAMSON, B. J., AND DZINDZIO, B. S. Disposition kinetics of quinidine, 30
UMEDA, T. (*See* Mahon et al.), 443

V

VANDER ELST, E. (*See* Branch et al.), 538
VANOV, S. K. (*See* Shah et al.), 732
VÖHRINGER, H. F., RIETBROCK, N., SPURNY, P., KUHLMANN, J., HAMPL, H., AND BAETHKE, R. Disposition of digitoxin in renal failure, 387

W

WADE, D. N. The background pattern of drug usage in Australia, 651
WAGNER, J. G. (*See* Wilkinson et al.), 213
WALKER, B. R. (*See* Shah et al.), 732
WALKER, J. (*See* Feinberg et al.), 782
WALTERS, P. G. Proposed procedural changes in new drug evaluation by the Food and Drug Administration, 700
WANG, R. I. H., STOCKDALE, S. L., AND HIEB, E. Hypnotic efficacy of lorazepam and flurazepam, 191
WAPNER, S. (*See* Conner et al.), 24
WEIDLER, D. J. (*See* Wilkinson et al.), 213
WEINTRAUB, M. (*See* Karch et al.), 489 (Commentary)
WELLING, P. G., LYONS, L. L., TSE, F. L. S., AND CRAIG, W. A. Propoxyphene and norpropoxyphene: Influence of diet and fluid on plasma levels, 559
WESTERHOLM, B. Sources of information on drug usage in Sweden, 644
WHITLOCK, R. M. L. (*See* Singh et al.), 493
WIERNIK, P. H. (*See* Smyth and Wiernik), 240
WILDER, B. J., AND RAMSAY, R. E. Oral and intramuscular phenytoin, 360
WILKINSON, G. R., AND SCHENKER, S., 486 (Correspondence)
—. (*See* McDevitt et al.), 396
WILKINSON, P. K., SEDMAN, A. J., SAKMAR, E., EARHART, R. H., WEIDLER, D. J., AND WAGNER, J. G. Blood ethanol concentrations during and following constant-rate intravenous infusion of alcohol, 213
WILLIAMS, F. H. (*See* Singh et al.), 493
WILLIAMS, F. M. (*See* Draffan et al.), 271
WILLIAMS, N. E. (*See* Calvey et al.), 813
WILLIAMS, R. L. (*See* Trenholme et al.), 459
WILLIAMSON, B. J. (*See* Ueda et al.), 30
WILSON, J. T., ATWOOD, G. F., AND SHAND, D. G. Disposition of propoxyphene and propranolol in children, 264
—. (*See* Rane et al.), 276
WILSON, T. W., 599 (Correspondence)
WINGERT, J. P., JR. (*See* Danowski et al.), 196
WOOSLEY, R. L. (*See* McDevitt et al.), 396
WORTHAM, G. F. (*See* Cressman et al.), 224

Y

YACOBI, A., UDALL, J. A., AND LEVY, G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect, 552
YAFFE, S. J. (*See* Gorodischer et al.), 256
YURCHAK, A. M. (*See* Hunt et al.), 546

Z

ZAGARELLA, J. (*See* Karim et al.), 158, 170, 177
ZIEGLER, V. E., CO, B. T., TAYLOR, J. R., CLAYTON, P. J., AND BIGGS, J. T. Amitriptyline plasma levels and therapeutic response, 795
ZWEIFLER, A. J., AND HANSSON, L. Heart rate responses during treatment of hypertension with propranolol, 403

Subject index

A

Absorption and excretion of tolmetin in man (Cressman et al.), 224
metabolism, and excretion of hydrochlorothiazide (Beermann et al.), 531
Acebutolol, basis for prediction of effect on exercise tolerance (Biron and Tremblay), 333
observations on pharmacokinetics of (Kaye et al.), 416
Acetaminophen elimination kinetics in neonates, children, and adults (Miller et al.), 284
Acetylmethadol, effects of, on plasma testosterone (Mendelson et al.), 371
Adriamycin, clinical comparison of, and combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma (Ahmann et al.), 821
Adults, neonates, children, and, acetaminophen elimination kinetics in (Miller et al.), 284
Airways resistance, specific, effects of cardioselective beta adrenoceptor blockade on, in normal subjects and in patients with bronchial asthma (Singh et al.), 493
Alcohol, blood ethanol concentrations during and following constant-rate intravenous infusion of (Wilkinson et al.), 213
Aluminum hydroxide mixture, magnesium and, influence of, on chlordiazepoxide absorption (Greenblatt et al.), 234
American Society for Clinical Pharmacology and Therapeutics, message from President, 249
notes of, 601
Seventy-seventh Annual Meeting, abstracts of papers, 103-120
Seventy-seventh Annual Meeting, meeting program, 97
Americas, variations in disease prevalence in (Cedillos), 675
Amitriptyline plasma levels and therapeutic response (Ziegler et al.), 795
Amobarbital, maternal and neonatal elimination of, after treatment of mother with barbiturates during late pregnancy (Draffan et al.), 271
Ampicillin, bacampicillin and, antibacterial activity and pharmacokinetics of (Rozencweig et al.), 592
pivampicillin and, in bile, portal and peripheral blood (Lund et al.), 587
Analgesia, aspirin and naproxen, assay of (Mahler et al.), 18
Angina, good clinical response to acebutolol in patients with, 333 (Biron and Tremblay), 333
Announcements, 250, 832
Antipyrine half-time in plasma, effect of arterial oxygen tension on (Cumming), 468
Arterial oxygen tension, effect of, on antipyrine half-time in plasma (Cumming), 468
Aspirin and naproxen analgesia, assay of (Mahler et al.), 18
Asthma, bronchial, effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with (Singh et al.), 493
Atenolol in essential hypertension (Myers et al.), 502
Australia, background pattern of drug usage in (Wade), 651
Azidomorphine; subjective effects and suppression of morphine abstinence (Clark et al.), 295

B

Bacampicillin and ampicillin, pharmacokinetics of, antibacterial activity and (Rozencweig et al.), 592
Bacterial, anti-, activity and pharmacokinetics of bacampicillin and ampicillin (Rozencweig et al.), 592
Barbiturates, treatment of mother with, during late pregnancy, maternal and neonatal elimination of amobarbital after (Draffan et al.), 271
Biliary elimination of diazepam in man (Mahon et al.), 443
excretion of digoxin in man (Caldwell and Cline), 410
Bioavailability and pharmacokinetics of phenytoin (Gugler et al.), 135
relative, and subjective effects of sodium salicylamide (Fleckenstein et al.), 451
of spironolactone (Karim et al.), 170
Biochemistry, genetics, and environmental factors, 607-627
Biometric problems, persistent, of UGDP study (Feinstein), 472 (Clinical biostatistics)

January, pp. 1-120; February, pp. 121-250; March, pp. 251-382; April, pp. 383-488; May, part 1, pp. 489-604; May, part 2, pp. 605-724; June, pp. 725-848.

Biostatistics, clinical (Feinstein)
XXXV. The persistent clinical failures and fallacies of the UGDP study, 78
XXXVI. The persistent biometric problems of the UGDP study, 472
Blood ethanol concentrations during and following constant-rate intravenous infusion of alcohol (Wilkinson et al.), 213
pressure, guanabenz effects on, and noninvasive parameters of cardiac performance in patients with hypertension (Shah et al.), 732
Books received, 96, 603
Bronchial asthma, effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with (Singh et al.), 493
Bumetanide, furosemide and; study of responses in normal English and German subjects (Branch et al.), 538
Bupivacaine, plasma protein binding and placental transfer of (Thomas et al.), 426
Butorphanol and morphine, intravenous, respiratory and circulatory effects of (Nagashima et al.), 738

C

Calcium balance in drug-induced osteomalacia; response to vitamin D (Peterson et al.), 63
Cannabidiol, influence of, on delta-9-tetrahydrocannabinol effects (Dalton et al.), 300
Canrenone—maximum and minimum steady-state plasma levels of, after spironolactone (Karim et al.), 177
Carbamazepine and its 10,11-epoxide metabolite in children, kinetics of (Rane et al.), 276
Cardiac arrhythmia, tocainide for chronic treatment of (McDevitt et al.), 396
effects of timolol and propranolol, duration of (Achong et al.), 148
performance in patients with hypertension, guanabenz effects on blood pressure and noninvasive parameters of (Shah et al.), 732
subjects, normal and, metabolism of procainamide in (Giardina et al.), 339
surgery patients, kinetics of high-dose intravenous morphine in (Stanski et al.), 752
Cardioselective beta adrenoceptor blockade, effects of, on specific airways resistance in normal subjects and in patients with bronchial asthma (Singh et al.), 493
Cefazolin, pharmacokinetics and hemodialyzability of, in uremic patients (Craig and Rifkin), 825
Chemotherapy, combination, of adult acute lymphocytic leukemia (Smyth and Wiernik), 240
Children, disposition of propoxyphene and propranolol in (Wilson et al.), 264
Children—cont'd.
kinetics of carbamazepine and its 10,11-epoxide metabolite in (Rane et al.), 276
neonates, and adults, acetaminophen elimination kinetics in (Miller et al.), 284
Chlordiazepoxide absorption, influence of magnesium and aluminum hydroxide mixture on (Greenblatt et al.), 234
Cigarettes, reactions to, as function of nicotine and "tar" (Goldfarb et al.), 767
Circulation, portal, pivampicillin hydrolyzed to ampicillin before absorption into (Lund et al.), 587
Circulatory effects, respiratory and, of intravenous butorphanol and morphine (Nagashima et al.), 738
Clindamycin absorption and elimination, erythromycin and, in pregnant women (Philipson et al.), 68
Clinical biostatistics (Feinstein)
XXXV. The persistent clinical failures and fallacies of the UGDP study, 78
XXXVI. The persistent biometric problems of the UGDP study, 472
pharmacologic training, drug evaluation, educational system, and, in small country (Hvidberg), 718
Pharmacology and Therapeutics, American Society for, message from President, 249
notes of, 601
Seventy-seventh Annual Meeting, abstracts of papers, 103-120
Seventy-seventh Annual Meeting, meeting program, 97
psychopharmacology, present status of (Berger), 725 (Commentary)
trial methodology, 628-643
in intestinal parasitic diseases (Botero), 630
Clofibrate, halofenate, and placebo, one-year trials with (Dujovne et al.), 352
Clonidine, clinical pharmacology and pharmacokinetics of (Dollery et al.), 11
Coagulant, anti-, effect, serum protein binding as determinant of warfarin body clearance and (Yacobi et al.), 552
Coronary disease, effects of marijuana in, 94 (Correspondence)
Cough, chronic, antitussive activity of diphenhydramine in (Lilienfield et al.), 421
Culture, morbidity, and effects of drugs (Blackwell), 668
Cytochrome P-450–mediated hepatic oxidations, effects of lead intoxications on (Alvares et al.), 183

D

Demethylation, intestinal absorption, and enterohepatic circulation of imipramine (Dencker et al.), 584
Depressive, anti-, effect of imipramine, plasma levels and (Gram et al.), 318

Desipramine, antidepressant levels of imipramine and (Gram et al.), 318
Developing country, patterns and problems of drug consumption in (Káldor), 657
Dextroamphetamine, effects of, on psychomotor skills (Evans et al.), 777
Dialysate, cefazolin administered by means of, in uremic patients on hemodialysis (Craig and Rifkin), 825
Diazepam, biliary elimination of, in man (Mahon et al.), 443
Diet and fluid, influence of, on plasma levels; propoxyphene and norpropoxyphene (Welling et al.), 559
Digitoxin in renal failure, disposition of (Vöhringer et al.), 387
Digoxin, biliary excretion of, in man (Caldwell and Cline), 410
  completely absorbed oral preparation of (Johnson et al.), 746
  concentrations, 599 (Correspondence)
  myocardium, human serum and (Härtel et al.), 153
  tissue and erythrocyte distribution of, in infants (Gorodischer et al.), 256
Diphenhydramine, antitussive activity of, in chronic cough (Lilienfield et al.), 421
Disease(s), geographic epidemiology of, how study of can help in detection of adverse drug reactions (Stolley), 679
  intestinal parasitic, clinical trial methodology in (Botero), 630
  prevalence in Americas, variations in (Cedillos), 675
    and variability of, 668-688
Dosage regimens for ethosuximide (Buchanan et al.), 143
Drug(s) consumption in developing country, patterns and problems of (Káldor), 657
  culture, morbidity, and effects of (Blackwell), 668
  evaluation, educational system, and clinical pharmacologic training in small country (Hvidberg), 718
    new, proposed procedural changes in, by Food and Drug Administration (Walters), 700
  -induced osteomalacia, calcium balance in; response to vitamin D (Peterson et al.), 63
  lag, scooped by; bureaucratic determinant of scientific precedence or (Morgan), 383 (Commentary)
  oxidation rates in hereditary hepatic porphyria; studies in porphyria (Anderson et al.), 47
  reactions, adverse, how study of geographic epidemiology of disease can help in detection of (Stolley), 679
    matter of opinion (Karch et al.), 489 (Commentary)
  regulation in United Kingdom (Dollery), 689
Drugs—cont'd.
  research, present dilemma of (Gross), 1 (Commentary)
  usage in Australia, background pattern of (Wade), 651
    in Sweden, sources of information on (Westerholm), 644
  utilization, patterns of, 644-667

E

Edrophonium in man, plasma concentration of (Calvey et al.), 813
Education and training, patterns of, 718-724
Educational system, drug evaluation, and clinical pharmacologic training in small country (Hvidberg), 718
Electroencephalographic sleep patterns, effects of marijuana extract and tetrahydrocannabinol on (Feinberg et al.), 782
Enterohepatic circulation, intestinal absorption, demethylation, and, of imipramine (Dencker et al.), 584
Environmental factors, biochemistry, genetics, and, 607-627
Epidemiology, geographic, of disease, how study of can help in detection of adverse drug reactions (Stolley), 679
Erythrocyte distribution, tissue and, of digoxin in infants (Gorodischer et al.), 256
Erythromycin and clindamycin absorption and elimination in pregnant women (Philipson et al.), 68
Ethanol, blood, concentrations during and following constant-rate intravenous infusion of alcohol (Wilkinson et al.), 213
Ethosuximide dosage regimens (Buchanan et al.), 143
Excretion, absorption and, of tolmetin in man (Cressman et al.), 224
  metabolism, absorption, and, of hydrochlorothiazide (Beermann et al.), 531
Exercise tolerance, basis for prediction of effect of acebutolol on (Biron and Tremblay), 333

F

Fever, induced, quinine disposition during malaria and (Trenholme et al.), 459
Flurazepam, lorazepam and, hypnotic efficacy of (Wang et al.), 191
  sleep laboratory studies of; model for evaluating hypnotic drugs (Kales et al.), 576
Food and Drug Administration, proposed procedural changes in new drug evaluation by (Walters), 700
Furosemide and bumetanide; study of responses in normal English and German subjects (Branch et al.), 538
  dosage regimen and natriuretic response to, 598 (Correspondence)

G

Genetics, biochemistry, and environmental factors, 607-627

Geographic epidemiology of disease, how study of can help in detection of adverse drug reactions (Stolley), 679

Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension (Shah et al.), 732

H

Halofenate, clofibrate, and placebo, one-year trials with (Dujovne et al.), 352

and propranolol, interaction between (Huffman et al.), 807

Hamilton scores; amitriptyline plasma levels and therapeutic response (Ziegler et al.), 795

Heart rate responses during treatment of hypertension with propranolol (Zweifler and Hansson), 403

Hemodialysis, cefazolin administered by means of dialysate in uremic patients on (Craig and Rifkin), 825

Hemodialyzability, pharmacokinetics and, of cefazolin in uremic patients (Craig and Rifkin), 825

Hepatic oxidations, cytochrome P-450–mediated, effects of lead intoxication on (Alvares et al.), 183

porphyria, hereditary, drug oxidation rates in; studies in porphyria (Anderson et al.), 47

Hereditary hepatic porphyria, drug oxidation rates in; studies in porphyria (Anderson et al.), 47

Hormone–like effects, thyroid, without thyrotoxicosis during one year's therapy with NA-DT_3 for hypercholesterolemia (Danowski et al.), 196

Human serum and myocardium digoxin (Härtel et al.), 153

Hydrochlorothiazide, absorption, metabolism, and excretion of (Beermann et al.), 531

combination of oxprenolol and, effective in patients with hypertension (Materson et al.), 325

Hydroxide mixture, aluminum, influence of magnesium and, on chlordiazepoxide absorption (Greenblatt et al.), 234

Hypercholesterolemia, thyroid hormone-like effects without thyrotoxicosis during one year's therapy with NA-DT_3 for (Danowski et al.), 196

Hypertension, combination of oxprenolol and hydrochlorothiazide effective in patients with (Materson et al.), 325

essential, atenolol in (Myers et al.), 502

Hypertension—cont'd.

guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with (Shah et al.), 732

heart rate responses during treatment of, with propranolol (Zweifler and Hansson), 403

Hypnotic drugs, model for evaluating; sleep laboratory studies of flurazepam (Kales et al.), 576

efficacy of lorazepam and flurazepam (Wang et al.), 191

Hypothyroid patients, rise in serum T3 in, after T4 therapy (Kahn), 523

I

Ifosfamide, divided-dose, pharmacokinetics of (Nelson et al.), 365

Imidazole carboxamide, combination of methyl-CCNU and, in disseminated malignant melanoma, clinical comparison of adriamycin and (Ahmann et al.), 821

Imipramine, intestinal absorption, demethylation, and enterohepatic circulation of (Dencker et al.), 584

plasma levels and antidepressive effect of (Gram et al.), 318

India, regulatory milieu in (Sheth), 704

Infants, tissue and erythrocyte distribution of digoxin in (Gorodischer et al.), 256

Intestinal absorption, demethylation, and enterohepatic circulation of imipramine (Dencker et al.), 584

parasitic diseases, clinical trial methodology in (Botero), 630

Intoxication, lead, effects on cytochrome P-450–mediated hepatic oxidations (Alvares et al.), 183

Isoniazid, acetylation of, variations between individuals and populations in, and its significance for treatment of pulmonary tuberculosis (Ellard), 610

J

Japan, systems in; regulatory differences and similarities (Sakuma), 694

K

Kidneys, liver and, rapid fall in plasma edrophonium due to rapid uptake by (Calvey et al.), 813

Kinetics, acetaminophen elimination, in neonates, children, and adults (Miller et al.), 284

of carbamazepine and its 10,11-epoxide metabolite in children (Rane et al.), 276

disposition, of quinidine (Ueda et al.), 30

Kinetics—cont'd.
of two oral forms of quinidine (Mahon et al.), 566
of high-dose intravenous morphine in cardiac surgery patients (Stanski et al.), 752
of oral antiarrhythmic lidocaine congener, tocainide (Lalka et al.), 757

L

Lead intoxication, effects on cytochrome P-450–mediated hepatic oxidations (Alvares et al.), 183
Leukemia, adult acute lymphocytic, combination chemotherapy of (Smyth and Wiernik), 240
Lidocaine congener, oral antiarrhythmic, tocainide, kinetics of (Lalka et al.), 757
tocainide, antiarrhythmic effects of, in man (McDevitt et al.), 396
effect of, on right ventricular muscle refractoriness (Engel et al.), 515
Liver and kidneys, rapid fall in plasma edrophonium due to rapid uptake by (Calvey et al.), 813
Lorazepam and flurazepam, hypnotic efficacy of (Wang et al.), 191
and pentobarbital as surgical premedicants, evaluation of (Conner et al.), 24
L-thyroxine, serum triiodothyronine levels in patients receiving (Kahn), 523
Lymphocytic leukemia, adult acute, combination chemotherapy of (Smyth and Wiernik), 240

M

Magnesium and aluminum hydroxide mixture, influence of, on chlordiazepoxide absorption (Greenblatt et al.), 234
Malaria, quinine disposition during, and during induced fever (Trenholme et al.), 459
Man, absorption and excretion of tolmetin in (Cressman et al.), 224
biliary elimination of diazepam in (Mahon et al.), 443
Marijuana, effects of, in coronary disease, 94 (Correspondence)
extract and tetrahydrocannabinol, effects of, on electroencephalographic sleep patterns (Feinberg et al.), 782
and T lymphocyte rosettes (Cushman and Khurana), 310
Maternal and neonatal elimination of amobarbital after treatment of mother with barbiturates during late pregnancy (Draffan et al.), 271
Medical Advisers in Pharmaceutical Industry, 247 (Correspondence)
Melanins, visceral, importance of studying (Altschule and Hegedus), 124 (Commentary)
Melanoma, disseminated malignant, clinical comparison of adriamycin and combination of methyl-CCNU and imidazole carboxamide in (Ahmann et al.), 821
Meperidine in man, pharmacokinetics of, 246 (Correspondence)
pharmacokinetics of, in man, 486 (Correspondence)
Metabolism, absorption, and excretion of hydrochlorothiazide (Beermann et al.), 531
and disposition of spironolactone (Karim et al.), 158
of procainamide in normal and cardiac subjects (Giardina et al.), 339
Metabolite(s), 10,11-epoxide, in children, kinetics of carbamazepine and (Rane et al.), 276
urinary, of theophylline, relationship of, to serum theophylline levels (Jenne et al.), 375
Methotrimeprazine, pharmacokinetics of, after single and multiple doses (Dahl), 435
Methyl-CCNU and imidazole carboxamide, combination of, in disseminated malignant melanoma, clinical comparison of adriamycin and (Ahmann et al.), 821
Morbidity, culture, and effects of drugs (Blackwell), 668
Morphine abstinence, subjective effects and; azidomorphine (Clark et al.), 295
high-dose intravenous, kinetics of, in cardiac surgery patients (Stanski et al.), 752
intravenous butorphanol and, respiratory and circulatory effects of (Nagashima et al.), 738
Mother, treatment of, with barbiturates during late pregnancy, maternal and neonatal elimination of amobarbital after (Draffan et al.), 271
Muscle refractoriness, right ventricular, effect of lidocaine on (Engel et al.), 515
Myocardium digoxin, human serum and (Härtel et al.), 153

N

N-acetylprocainamide, antiarrhythmic efficacy of, in patients with premature ventricular contractions (Lee et al.), 508
levels in patients with end-stage renal failure (Gibson et al.), 206
NA-DT_3 for hypercholesterolemia, thyroid hormone-like effects without thyrotoxicosis during one year's therapy with (Danowski et al.), 196
Nalidixinic acid and oxolinic acid in healthy women, pharmacokinetics of (Männistö), 37
Naltrexone, physiological and psychological effects of single doses (Gritz et al.), 773
Naproxen analgesia, aspirin and, assay of (Mahler et al.), 18

Neonatal elimination, maternal and, of amobarbital after treatment of mother with barbiturates during late pregnancy (Draffan et al.), 271
Neonates, children, and adults, acetaminophen elimination kinetics in (Miller et al.), 284
Nicotine and "tar," reactions to cigarettes as function of (Goldfarb et al.), 767
Norpropoxyphene, propoxyphene and; influence of diet and fluid on plasma levels (Welling et al.), 559

O

Oral and intramuscular phenytoin (Wilder and Ramsay), 360
Osteomalacia, drug-induced, calcium balance in; response to vitamin D (Peterson et al.), 63
Oxidation(s), cytochrome P-450–mediated hepatic, effects of lead intoxication on (Alvares et al.), 183
of methotrimeprazine in lumen or wall of gastrointestinal tract (Dahl), 435
rates, drug, in hereditary hepatic porphyria; studies in porphyria (Anderson et al.), 47
Oxolinic acid, nalidixinic acid and, in healthy women, pharmacokinetics of (Männistö), 37
Oxprenolol administered twice daily, antihypertensive effectiveness of (Materson et al.), 325
Oxygen tension, arterial, effect of, on antipyrine half-time in plasma (Cumming), 468

P

Parasitic diseases, intestinal, clinical trial methodology in (Botero), 630
Pentobarbital, lorazepam and, as surgical premedicants, evaluation of (Conner et al.), 24
Pharmaceutical Industry, Medical Advisers in, 247 (Correspondence)
Pharmacokinetics of acebutolol, observations on (Kaye et al.), 416
of bacampicillin and ampicillin, antibacterial activity and (Rozencweig et al.), 592
and bioavailability of phenytoin (Gugler et al.), 135
clinical pharmacology and, of clonidine (Dollery et al.), 11
of divided-dose ifosfamide (Nelson et al.), 365
and hemodialyzability of cefazolin in uremic patients (Craig and Rifkin), 825
of meperidine in man, 246, 486 (Correspondence)
of methotrimeprazine after single and multiple doses (Dahl), 435
of nalidixinic acid and oxolinic acid in healthy women (Männistö), 37
Pharmacologic training, clinical, drug evaluation, educational system, and, in small country (Hvidberg), 718
Pharmacology, clinical, and pharmacokinetics of clonidine (Dollery et al.), 11
Phenytoin, oral and intramuscular (Wilder and Ramsay), 360
pharmacokinetics and bioavailability of (Gugler et al.), 135
Physiological and psychological effects of single doses of naltrexone (Gritz et al.), 773
Pivampicillin and ampicillin in bile, portal and peripheral blood (Lund et al.), 587
Placebo, clofibrate, halofenate, and, one-year trials with (Dujovne et al.), 352
Placental transfer of bupivacaine, plasma protein binding and (Thomas et al.), 426
Plasma concentration of edrophonium in man (Calvey et al.), 813
effect of arterial oxygen tension on antipyrine half-time in (Cumming), 468
levels, amitriptyline, and therapeutic response (Ziegler et al.), 795
and antidepressive effect of imipramine (Gram et al.), 318
influence of diet and fluid on; propoxyphene and norpropoxyphene (Welling et al.), 559
maximun and minimum steady-state, of canrenone after spironolactone (Karim et al.), 177
nortriptyline level; amitriptyline plasma levels and therapeutic response (Ziegler et al.), 795
protein binding and placental transfer of bupivacaine (Thomas et al.), 426
testosterone, effects of acetylmethadol on (Mendelson et al.), 371
or urine, no evidence of pyrvinium in, after oral administration (Smith et al.), 802
Porphyria, studies in; drug oxidation rates in hereditary hepatic porphyria (Anderson et al.), 47
Pregnancy, late, treatment of mother with barbiturates during, maternal and neonatal elimination of amobarbital after (Draffan et al.), 271
Pregnant women, erythromycin and clindamycin absorption and elimination in (Philipson et al.), 68
Procainamide, efficacy of, compared with N-acetylprocainamide in patients with premature ventricular contractions (Lee et al.), 508
metabolism of, in normal and cardiac subjects (Giardina et al.), 339
renal elimination of (Galeazzi et al.), 55, 830 (Correspondence)
Progress with protection (Modell), 121 (Editorial)
Propoxyphene and norpropoxyphene; influence of diet and fluid on plasma levels (Welling et al.), 559
and propranolol, disposition of, in children (Wilson et al.), 264

Propranolol, halofenate and, interaction between (Huffman et al.), 807
heart rate responses during treatment of hypertension with (Zweifler and Hansson), 403
propoxyphene and, disposition of, in children (Wilson et al.), 264
timolol and, duration of cardiac effects of (Achong et al.), 148
Protection, progress with (Modell), 121 (Editorial)
Protein binding, plasma, and placental transfer of bupivacaine (Thomas et al.), 426
serum, as determinant of warfarin body clearance and anticoagulant effect (Yacobi et al.), 552
Psychological effects, physiological and, of single doses of naltrexone (Gritz et al.), 773
Psychomotor skills, effects of dextroamphetamine on (Evans et al.), 777
Psychopharmacology, clinical, present status of (Berger), 725 (Commentary)
Public service, sponsored tasks and (Sicé), 251 (Editorial)
Pulmonary tuberculosis, variations between individuals and populations in acetylation of isoniazid and its significance for treatment of (Ellard), 610
Pyrvinium pamoate, absorption of (Smith et al.), 802

Q

Quinidine, disposition kinetics of (Ueda et al.), 30
of two oral forms of (Mahon et al.), 566
Quinine disposition during malaria and during induced fever (Trenholme et al.), 459

R

Reactions, adverse drug—matter of opinion (Karch et al.), 489
Regulatory differences and similarities, 689-717
systems in Japan (Sakuma), 694
milieu in India (Sheth), 704
Renal elimination of procainamide (Galeazzi et al.), 55, 830 (Correspondence)
failure, disposition of digitoxin in (Vöhringer et al.), 387
end-stage, N-acetylprocainamide levels in patients with (Gibson et al.), 206
Research, drug, present dilemma of (Gross), 1
Respiratory and circulatory effects of intravenous butorphanol and morphine (Nagashima et al.), 738
Rosettes, T lymphocyte, marijuana and (Cushman and Khurana), 310

S

Salicylamide, sodium; relative bioavailability and subjective effects (Mahon et al.), 451
Scientific precedence, bureaucratic determinant of; "scooped by drug lag" (Morgan), 383 (Commentary)
Serum, human, and myocardium digoxin (Härtel et al.), 153
Serum—cont'd.
protein binding as determinant of warfarin body clearance and anticoagulant effect (Yacobi et al.), 552
theophylline levels, relationship of urinary metabolites of theophylline to (Jenne et al.), 375
triiodothyronine levels, serum, in patients receiving L-thyroxine (Kahn), 523
Service, public, sponsored tasks and (Sicé), 251 (Editorial)
Sleep laboratory studies of flurazepam; model for evaluating hypnotic drugs (Kales et al.), 576
patterns, electroencephalographic, effects of marijuana extract and tetrahydrocannabinol on (Feinberg et al.), 782
Smoking, effect of, on theophylline disposition (Hunt et al.), 546
Sodium salicylamide; relative bioavailability and subjective effects (Fleckenstein et al.), 451
Spironolactone, bioavailability of (Karim et al.), 170
canrenone—maximum and minimum steady-state plasma levels of (Karim et al.), 177
disposition and metabolism of (Karim et al.), 158
Surgical premedicants, evaluation of lorazepam and pentobarbital as (Conner et al.), 24
Sweden, drug usage in, sources of information on (Westerholm), 644

T

T lymphocyte rosettes, marijuana and (Cushman and Khurana), 310
"Tar," nicotine and, reactions to cigarettes as function of (Goldfarb et al.), 767
Tasks, sponsored, and public service (Sicé), 251 (Editorial)
Testosterone, plasma, effects of acetylmethadol on (Mendelson et al.), 371
Tetrahydrocannabinol effects, delta-9-, influence of cannabidiol on (Dalton et al.), 300
of marijuana extract and, on electroencephalographic sleep patterns (Feinberg et al.), 782
Theophylline disposition, effect of smoking on (Hunt et al.), 546
urinary metabolites of, relationship of, to serum theophylline levels (Jenne et al.), 375
Therapeutic response, amitriptyline plasma levels and (Ziegler et al.), 795
Thyroid hormone–like effects without thyrotoxicosis during one year's therapy with NA-DT_3 for hypercholesterolemia (Danowski et al.), 196
Thyrotoxicosis, thyroid hormone–like effects without, during one year's therapy with NA-DT_3 for hypercholesterolemia (Danowski et al.), 196
Timolol and propranolol, duration of cardiac effects of (Achong et al.), 148

Tissue and erythrocyte distribution of digoxin in infants (Gorodischer et al.), 256
Tocainide, 2-amino-2′,6′-propionoxylidide, lidocaine congener, antiarrhythmic effects of, in man (McDevitt et al.), 396
oral antiarrhythmic lidocaine congener, kinetics of (Lalka et al.), 757
Tolmetin, absorption and excretion of, in man (Cressman et al.), 224
Training, education and, patterns of, 718-724
Triiodothyronine levels, serum, in patients receiving L-thyroxine (Kahn), 523
Tuberculosis, pulmonary, variations between individuals and populations in acetylation of isoniazid and its significance for treatment of (Ellard), 610

U

UGDP study, persistent biometric problems of (Feinstein), 472 (Clinical biostatistics)
clinical failures and fallacies of (Feinstein), 78
United Kingdom, drug regulation in (Dollery), 689
Uremic patients, pharmacokinetics and hemodialyzability of cefazolin in (Craig and Rifkin), 825
Urinary metabolites of theophylline, relationship of, to serum theophylline levels (Jenne et al.), 375
Urine, plasma or, no evidence of pyrvinium in, after oral administration (Smith et al.), 802

V

Ventricular contractions, premature, antiarrhythmic efficacy of N-acetylprocainamide in patients with (Lee et al.), 508
muscle refractoriness, right, effect of lidocaine on (Engel et al.), 515
Visceral melanins, importance of studying (Altschule and Hegedus), 124 (Commentary)
Vitamin D, response to; calcium balance in drug-induced osteomalacia (Peterson et al.), 63

W

Warfarin body clearance and anticoagulant effect, serum protein binding as determinant of (Yacobi et al.), 552
Women, healthy, pharmacokinetics of nalidixinic acid and oxolinic acid in (Männistö), 37
pregnant, erythromycin and clindamycin absorption and elimination in (Philipson et al.), 68